2007: Late-Breaking Posters

Late-Breaking Posters

L1

Milnacipran Efficacy in the Treatment of Fibromyalgia Syndrome: A 15-Week, Randomized, Double-Blind, Placebo-Controlled Trial

L2

Placebo-Controlled Pilot Study of Rilonacept (IL-1 Trap), A Long Acting IL-1 Inhibitor, In Refractory Chronic Active Gouty Arthritis

L4

Intra-articular Botulinum Toxin Type A (IA-BoNT/A) Significantly Decreases Shoulder Pain in Patients with Refractory Shoulder Pain due to Osteoarthritis: A Randomized Double-Blind Placebo-Controlled Trial

L5

Increase in vertebral fracture risk In postmenopausal women using Omeprazole.

L6

Targeted Inhibition of IL-6 Signalling withTocilizumab Improves Quality of Life and Function in Patients with Rheumatoid Arthritis with Inadequate Response to a Range of DMARDs

L7

TRU-015 Improves Rheumatoid Arthritis Disease Activity in a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 2 Dose Ranging Trial

L8

Predictors of Increased Carotid Intima Medial Thickness (CIMT) in the Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) Cohort

L9

Elevated Antiangiogenic Factors Predict Preeclampsia In Pregnant Patients With SLE And/Or APL Antibodies

L10

Golimumab, a New, Human, TNF-alpha Antibody Administered as a Monthly Subcutaneous Injection in Ankylosing Spondylitis (AS): 24-Week Efficacy and Safety Results of the Randomized, Placebo-Controlled GO-RAISE Study

L11

A Randomised Controlled Trial of Infliximab shows clinical and MRI efficacy in patients with HLA B27 positive very early ankylosing spondylitis

L12

A Multi-center Crossover Study of MQX-503, a Topical Formulation of Nitroglycerin, in Patients with Raynaud’s Phenomenon

See more of: Late-Breaking Abstracts Poster Sessions

<< Previous Session Level | Next Session Level >>